Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA)
CRC-SCA is a natural history study funded by the National Ataxia Foundation (NAF). The study enrolls individuals who have a confirmed diagnosis of SCA 1, 2, 3, 6, 7, 8, 10, 27B, or RFC1/CANVAS. Participants enrolled in CRC-SCA have extensive longitudinal clinical data available, with a cross-sectional biospecimen collection added in 2020. In 2023, CRC-SCA expanded to include follow-up biospecimen collections for a subset of participants.
Study Participants
This study is still currently enrolling and projects to have a total enrollment of 200 subjects. Biospecimens are available from unaffected individuals with a family history of SCA1/SCA3 and participants with a recent diagnosis of SCA1 or SCA3.
Enrollment in CRC-SCA overlaps significantly with the Clinical Trial Readiness Study for SCA1 and SCA3 (READISCA), which is also banked with BioSEND.
Available Data
CLINICAL: performance, observational, and self-reported assessments of motor, cognitive, and functional staging
GENETIC: SCA mutation/CAG repeat length
Available Biospecimens
Plasma, serum, CSF, whole blood, and DNA.
CRC-SCA is funded by The National Ataxia Foundation. We kindly acknowledge the patients involved in this consortium for their generous contributions to this research.